Day One Biopharmaceuticals, Inc.
DAWNDelisted Apr 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001845337
Day One Biopharmaceuticals, Inc. was delisted on Apr 23, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 208 institutions reported holding it in 13F filings for Q1 2026, worth $1.85B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:42 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $107.3B (67847.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K/A | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 26, 2024 | Mar 6, 2023 | Mar 7, 2022 |
| Revenue | $158.2M | $131.2M | – | – | – |
| Operating expenses | $285.9M | $348.4M | $206.1M | $146.9M | $72.7M |
| Research and development | $148.1M | $227.7M | $130.5M | $85.6M | $43.6M |
| Selling, general and administrative | $120.6M | $115.5M | $75.5M | $61.3M | $29.2M |
| Operating income | -$127.8M | -$217.3M | -$206.1M | -$146.9M | -$72.7M |
| Income tax | -$1.98M | $7.14M | – | – | – |
| Net income | -$107.3B | -$95.5M | -$188.9M | -$142.2M | -$72.8M |
| EPS, basic | $-1.04 | $-1.02 | $-2.37 | $-2.17 | – |
| EPS, diluted | $-1.04 | $-1.02 | $-2.37 | $-2.17 | – |
| Weighted shares, basic | 103.2M | 93.2M | 79.8M | 65.5M | – |
| Weighted shares, diluted | 103.2M | 93.2M | 79.8M | 65.5M | – |
| Margins and growth | |||||
| Operating margin | -80.8% | -165.7% | – | – | – |
| Net margin | -67847.2% | -72.8% | – | – | – |
| Revenue growth, year over year | +20.6% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 26, 2024 | Mar 6, 2023 | Mar 7, 2022 |
| Cash and equivalents | $197.1M | $125.0M | $230.8M | $85.3M | $284.3M |
| Short-term investments | $244.0M | $406.8M | $135.6M | $257.0M | – |
| Accounts receivable | $26.7M | $13.9M | – | – | – |
| Inventory | $6.33M | $3.32M | – | – | – |
| Total current assets | $485.1M | $562.3M | $375.3M | $347.9M | $289.4M |
| Property, plant and equipment | $2.14M | $2.29M | $208.0K | $20.0K | $57.0K |
| Intangible assets | $18.0M | $15.6M | – | – | – |
| Total assets | $507.8M | $582.8M | $376.0M | $349.1M | $289.8M |
| Accounts payable | $3.73M | $3.26M | $2.58M | $260.0K | $1.74M |
| Total current liabilities | $60.5M | $73.5M | $29.5M | $16.6M | $8.66M |
| Total liabilities | $66.7M | $80.0M | $29.5M | $17.0M | $8.67M |
| Shareholders' equity | $441.2M | $502.8M | $346.5M | $332.0M | $281.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 26, 2024 | Mar 6, 2023 | Mar 7, 2022 |
| Operating cash flow | -$103.8M | -$78.1M | -$146.9M | -$109.9M | -$48.5M |
| Capital expenditures | $320.0K | $2.17M | $224.0K | $26.0K | $0 |
| Free cash flow | -$104.1M | -$80.3M | -$147.1M | -$109.9M | -$48.5M |
| Depreciation and amortization | $366.0K | $92.0K | $36.0K | $63.0K | $20.0K |
| Stock-based compensation | $44.4M | $48.3M | $39.3M | $27.2M | $13.3M |
| Investing cash flow | $174.6M | -$231.0M | $128.4M | -$255.1M | -$8.00M |
| Financing cash flow | $1.22M | $203.3M | $164.0M | $165.9M | $297.1M |
| Net change in cash | – | – | $145.5M | -$199.0M | $240.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 28.1% | 36.8% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 15, 2026 | 103.3M | +1.9% | SEC |
| Feb 19, 2026 | 103.3M | +1.9% | SEC |
| Oct 31, 2025 | 102.7M | +1.8% | SEC |
| Jul 31, 2025 | 102.4M | +16.7% | SEC |
| May 1, 2025 | 101.4M | +16.0% | SEC |
| Feb 20, 2025 | 101.4M | +16.0% | SEC |
| Oct 24, 2024 | 100.8M | +15.9% | SEC |
| Jul 31, 2024 | 87.8M | +0.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.